0000899243-19-023627.txt : 20190916
0000899243-19-023627.hdr.sgml : 20190916
20190916161520
ACCESSION NUMBER: 0000899243-19-023627
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190916
FILED AS OF DATE: 20190916
DATE AS OF CHANGE: 20190916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SULIMAN SHEHNAAZ
CENTRAL INDEX KEY: 0001713070
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39035
FILM NUMBER: 191094872
MAIL ADDRESS:
STREET 1: 901 GATEWAY BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 10x Genomics, Inc.
CENTRAL INDEX KEY: 0001770787
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 455614458
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
BUSINESS PHONE: (925) 401-7300
MAIL ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER COMPANY:
FORMER CONFORMED NAME: 10X Genomics, Inc.
DATE OF NAME CHANGE: 20190315
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-16
0
0001770787
10x Genomics, Inc.
TXG
0001713070
SULIMAN SHEHNAAZ
C/O 10X GENOMICS, INC.
6230 STONERIDGE MALL ROAD
PLEASANTON
CA
94588
1
0
0
0
Stock Option (right to buy)
30.00
2019-09-16
4
J
0
100000
0.00
D
2029-08-07
Class B Common Stock
100000
0
D
Stock Option (right to buy)
30.00
2019-09-16
4
J
0
100000
0.00
A
2029-08-07
Class A Common Stock
100000
100000
D
Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.
One forty-eighth of the shares subject to the option vested on September 7, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares.
/s/ Eric S. Whitaker, as Attorney-in-Fact
2019-09-16